EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma

Yulong Deng, Beibei Huang, Yuxing Tang, Qinyan Su, Hongquan Liu, Hongbo Mo, Huanhuan Tang, Kunhua Xiong, Shipei He, Yiwu Dang, Gang Chen, Minhua Rong

Frontiers in Bioscience-Landmark · 2026

DOI: 10.31083/fbl52385 ↗

At a glance

Journal article in Frontiers in Bioscience-Landmark, 2026. Written by Yulong Deng and 11 co-authors. Institution: Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China. Major MEDLINE topics: Liver Neoplasms, Carcinoma, Hepatocellular, Small Ubiquitin-Related Modifier Proteins, Metabolic Networks and Pathways. 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: Future Academic Star of Guangxi Medical University.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background:Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. However, the role of small ubiquitin-like modifier 2 (SUMO2), a core member of the small ubiquitin-like modifier (SUMO) family, regarding its expression patterns and metabolism-related functions in HCC remains inadequately understood.Methods:A multidimensional analytical framework was applied, integrating immunohistochemistry (153 HCC vs. 21 non-HCC samples), proteomics (159 paired samples), bulk transcriptomics (3240 HCC vs. 2267 non-HCC samples), single-cell RNA sequencing (RNA-seq) (10 HCC vs. 8 non-HCC samples), spatial transcriptomics, and external CRISPR/Cas9 functional genomics data. Systematic analyses included standardized mean difference (SMD), pathway enrichment, pseudotime trajectory inference, in silico knockout, cell–cell communication, metabolic flux scoring, immune infiltration, clinical correlation, drug sensitivity prediction, and molecular docking.Results:At the protein level, immunohistochemistry (nuclear positivity) and external proteomic data collectively demonstrated consistent SUMO2 overexpression in HCC. Consistent upregulation was also observed at the mRNA level across large-scale cohorts. Single-cell RNA-seq and spatial transcriptomics localized SUMO2 enrichment to malignant hepatocytes and tumor-dominant regions. CRISPR-mediated SUMO2 knockout suppressed proliferation in multiple HCC cell lines. Mechanistically, high SUMO2 expression was significantly associated with metabolic reprogramming involving glycolysis/gluconeogenesis, pyruvate metabolism, and the tricarboxylic acid cycle. SUMO2-high malignant hepatocyte subpopulations exhibited enhanced activity of the macrophage migration inhibitory factor signaling axis and enhanced iron-sensor interactions. Further, the immune infiltration analysis revealed a negative correlation between SUMO2 expression and M1 macrophages and a positive correlation between follicular helper T cells and regulatory T cells. Clinically, elevated SUMO2 levels were found to be associated with adverse prognostic features. Furthermore, high SUMO2 expression was associated with increased sensitivity to dasatinib, and molecular docking simulations predicted potential binding between SUMO2 and dasatinib, with a Vina score of −8.5 kcal/mol.Conclusions:SUMO2 is aberrantly expressed at the protein, mRNA, single-cell, and spatial transcriptomic levels in HCC and is significantly associated with metabolic reprogramming and altered migration inhibitory factor (MIF)-mediated intercellular communication, suggesting its potential as a novel biomarker for diagnosis and treatment.

Subjects

MeSH terms (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularSmall Ubiquitin-Related Modifier ProteinsMetabolic Networks and PathwaysHumansGene Expression Regulation, NeoplasticSpatial TranscriptomicsProteomics

Author keywords

hepatocellular carcinomaimmunohistochemistrymacrophage migration inhibitory factormetabolic reprogrammingsingle-cell RNA sequencingsmall ubiquitin-like modifier 2spatial transcriptomics

Substances

Small Ubiquitin-Related Modifier ProteinsSUMO2 protein, human

Authors and institutions

  • Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 530021 Nanning, Guangxi, China.
  • Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 530021 Nanning, Guangxi, China.

Funding

  • Future Academic Star of Guangxi Medical University

Cite

APA

Deng, Y., Huang, B., Tang, Y., Su, Q., Liu, H., Mo, H., Tang, H., Xiong, K., He, S., Dang, Y., Chen, G., & Rong, M. (2026). Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl52385

Vancouver

Deng Y, Huang B, Tang Y, Su Q, Liu H, Mo H, et al. Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl52385

BibTeX
@article{Deng2026,
  author = {Deng, Yulong and Huang, Beibei and Tang, Yuxing and Su, Qinyan and Liu, Hongquan and Mo, Hongbo and Tang, Huanhuan and Xiong, Kunhua and He, Shipei and Dang, Yiwu and Chen, Gang and Rong, Minhua},
  title = {Multimodal Analysis Reveals Aberrant Expression of SUMO2 and Its Significant Association With Key Mechanisms of Metabolic Pathways in Hepatocellular Carcinoma},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  doi = {10.31083/fbl52385}
}
Start for free →